Published in Curr Hematol Rep on July 01, 2004
Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1 alpha. Blood (2008) 2.09
Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood (2004) 1.74
Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis. Am J Respir Crit Care Med (2014) 1.53
Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther (2009) 1.46
A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med (2014) 1.42
Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther (2007) 1.40
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment. Genes Dev (2012) 1.40
Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIV-based lentiviral vectors. Blood (2008) 1.37
Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood (2003) 1.37
Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood (2003) 1.35
Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR. Mol Ther (2009) 1.22
High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood (2010) 1.22
Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential. Cell Stem Cell (2008) 1.15
Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest (2003) 1.11
Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells. Biochem J (2011) 1.09
The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS One (2009) 1.07
Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease. Blood (2008) 1.02
Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A (2009) 1.00
Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood (2013) 0.98
Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD). J Biol Chem (2010) 0.98
Pathophysiology and therapy for haemoglobinopathies. Part I: sickle cell disease. Expert Rev Mol Med (2006) 0.98
Human CD34(+) and CD34(+)CD38(-) hematopoietic progenitors in sickle cell disease differ phenotypically and functionally from normal and suggest distinct subpopulations that generate F cells. Exp Hematol (2004) 0.97
Murine retroviral but not human cellular promoters induce in vivo erythroid-specific deregulation that can be partially prevented by insulators. Mol Ther (2007) 0.95
Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells. Mol Ther (2004) 0.94
Biomarkers for early detection of sickle nephropathy. Am J Hematol (2011) 0.92
Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13. J Clin Invest (2015) 0.90
Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency. PLoS One (2012) 0.87
RhoA GTPase controls cytokinesis and programmed necrosis of hematopoietic progenitors. J Exp Med (2013) 0.85
Therapy for beta-globinopathies: a brief review and determinants for successful and safe correction. Ann N Y Acad Sci (2010) 0.84
Genetic therapy for beta-thalassemia: from the bench to the bedside. Hematology Am Soc Hematol Educ Program (2010) 0.82
Pathophysiology and therapy for haemoglobinopathies. Part II: thalassaemias. Expert Rev Mol Med (2006) 0.82
Genetic correction of sickle cell anemia and beta-thalassemia: progress and new perspective. ScientificWorldJournal (2010) 0.80
Quantification of the 5-lipoxygenase inhibitor zileuton in human plasma using high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.80
The Authors Reply. JACC Cardiovasc Imaging (2016) 0.75
Report on the workshop "New Technologies in Stem Cell Research," Society for Pediatric Research, San Francisco, California, April 29, 2006. Stem Cells (2007) 0.75